Plain-English translation of NCT05283720 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called , given as an injection under the skin, in combination with other cancer drugs that you may already know about or that may be new to you. The study wants to learn whether this combination is safe, what side effects occur, and whether it helps shrink lymphomas that have come back after previous treatment or newly diagnosed lymphomas that haven't been treated yet.
Non-Hodgkin lymphoma is a serious cancer of immune cells, and many patients either don't respond well to standard treatments or experience a return of their disease. This trial exists to find out if combining this new immune-boosting medication with existing cancer drugs can offer better results and help more patients.
You will receive as an injection under the skin, usually on a schedule repeating every 21 to 56 days depending on which treatment arm you join, combined with oral pills or intravenous infusions of other cancer medications. You'll attend regular visits at a hospital or clinic for medical exams, blood tests, imaging scans, and questionnaires to check how well the treatment is working and monitor for side effects; expect a higher number of appointments and tests than you might receive with standard care alone.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States